Home▸Erectile Dysfunction Pharmacology▸Nitrate PDE5 Inhibitor Drug Interaction Simulator

💊 Nitrate PDE5 Inhibitor Drug Interaction Simulator

This simulation illustrates the dangerous interactions between nitrates and PDE5 inhibitors. It highlights the risks associated with combining these medications, providing critical information for healthcare providers to avoid adverse effects and ensure patient safety.

Erectile Dysfunction Pharmacology2DModerate60 FPS
nitrate-pde5-inhibitor-interaction-simulator ↗ Open standalone

Sildenafil Blocks cGMP Breakdown In Smooth Muscle

PDE5 inhibitors raise cGMP, causing mild, safe vasodilation.

  • 5–8: Systolic BP drop (mmHg typical)
  • >80%: PDE5 inhibition (enzyme blocked)
  • 30–60: Onset of action (minutes)
  • ~4: Half-life (hours (sildenafil))

How PDE5 inhibitors work

Sildenafil blocks PDE5 from degrading cGMP in vessels.

Alone, PDE5 inhibitors cause only modest, safe vasodilation.

Localized vascular effect

Effect concentrates in corpus cavernosum smooth muscle.

Systemic circulation stays stable

Blood pressure drops slightly but stays in safe range.

Nitroglycerin Donates Nitric Oxide To Vessel Walls

Nitrates release nitric oxide, also raising cGMP modestly.

  • 10–15: Systolic BP drop (mmHg typical)
  • 1–3: NO donation onset (min sublingual)
  • Direct: Guanylate cyclase (activation)
  • ~2–3: Half-life (min (nitroglycerin))

Nitric oxide release mechanism

Nitrates metabolize into nitric oxide inside vessel walls.

Alone, nitrates cause controlled, reversible vasodilation.

Direct guanylate cyclase activation

NO activates guanylate cyclase, raising cGMP directly.

Coronary and systemic dilation

Vessels widen enough to relieve angina safely.

Both Drugs Raise cGMP Through The Same Pathway

Taking both drugs together activates one pathway twice.

  • >90%: Combined cGMP (activation)
  • Shared: Pathway overlap (cGMP cascade)
  • Contra-: Risk class (indicated)
  • Minutes: Crisis onset (after dosing)

Shared molecular pathway

Both drugs converge on the nitric oxide–cGMP cascade.

Combining nitrates and PDE5 inhibitors is a known contraindication.

No independent regulation

Neither drug can compensate for the other's excess.

Vasculature-wide exposure

Effects now reach vessels throughout the entire body.

Systemic Vessels Dilate Far Beyond Safe Limits

Vessel walls relax excessively across the whole body.

  • >60%: Tone lost (vascular tone)
  • Significant: Venous pooling (blood pools)
  • Sharply: Cardiac preload (reduced)
  • Insufficient: Reflex response (to compensate)

Excessive smooth muscle relaxation

Vessel walls lose nearly all baseline muscular tone.

Synergy multiplies the effect, it does not simply add it.

Venous pooling and reduced return

Blood pools in veins, reducing return to the heart.

Compensation begins failing

Baroreceptor reflexes cannot offset the sudden drop.

Blood Pressure Collapses Toward Cardiovascular Shock

Severe hypotension threatens organ perfusion and life.

  • <70: Systolic BP (mmHg possible)
  • MI / stroke: Major risk (organ ischemia)
  • IV fluids: Emergency care (+ vasopressors)
  • Significant: Mortality risk (if untreated)

Cardiovascular collapse risk

Organs lose adequate blood flow and oxygen delivery.

This is a documented cause of death from drug interaction.

Emergency management

Treatment requires fluids and vasopressor support urgently.

Absolute prevention

Patients must never combine these drug classes.

⚙ Under the hood

This simulation illustrates the dangerous interactions between nitrates and PDE5 inhibitors. It highlights the risks associated with combining these medications, providing critical information for healthcare providers to avoid adverse effects and ensure patient safety.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)